SUMMARY Methyl tertiary butyl ether (MTBE) rapidly dissolves cholesterol gall stones in vitro and in vivo. To further characterise tolerability and safety of this aliphatic ether, either MTBE (1 ml/kg body wt daily for two days) or an equal amount of saline was infused into the common bile duct (CBD) ofeight cholecystectomised rabbits. Transient vomiting, dyspnoea and somnolence developed during MTBE instillation. Post-treatment values of serum transaminases and alkaline phosphatase were significantly higher in MTBE than in saline treated animals. Cholangiography one week after the last intraductal infusion showed a five-fold increase of CBD size in MTBE v control rabbits. At autopsy histological signs of chemical cholangitis and mild duodenitis were noted in MTBE treated animals. Prompted by these findings, we performed a cholangiography in two patients who had received intraductal MTBE (about 0-2 ml/kg body wt daily for one or two days) one year before: an abnormal dilatation of the CBD was present, which might represent a specific, hitherto undescribed permanent sequela of MTBE administration. 
Methvl tertiary butyl ether (MTBE) is a foul smelling volatile, inflammable aliphatic ether used as an octane enhancer in lead free petrol.' Methyl tertiary butyl ether has a cholesterol solubilising capacity of 14 g/dl and rapidly dissolves cholesterol gall stones in vitro.2 By direct instillation, MTBE required for to 16 hours to dissolve gall stones surgically implanted in canine gall bladder.' Dogs tolerated MTBE infusions into the gall bladder with minor clinical and biochemical side effects. On light microscopy, however, inflammatory changes of the gall bladder and occasional signs of duodenitis were detected.
Clinical experience with MTBE infused into the gall bladder for the treatment of cholesterol stones has shown three main side effects -that is, sedation, burning upper abdominal pain at the start of each infusion, and possible maceration and disruption of catheters made of percuflex material.34 Intraductal administration of low dose MTBE produced minor signs of systemic toxicity in small series of patients."7 To further assess the immediate and delayed effects of MTBE administration, we planned to inject this compound directly into the common bile duct (CBD) of cholecystectomised rabbits. In addition, we thought it of interest to extend our evaluation to two patients previously treated with intraductal MTBE for residual CBD stones.
Methods

ANIMAL EXPERIMENTS
Eight female New Zealand rabbits (Charles River, Italy), weighing about 3 kg, fasted overnight, were operated under anaesthesia induced with 25 mg/kg body wt of pentobarbital sodium.5 The gall bladder was removed and the cystic duct was cannulated with a polyethylene tubing (PP 10, Portex, England) whose external arm was placed subcutaneously. Experiments were delayed three days after surgery. At this point, the rabbits were reoperated under local anaesthesia: the skin was incised and the external 206 arm of the catheter was identified and exteriorised. The animals were randomly allocated to two groups: four rabbits were given intraductal MTBE (Fluka AG, Buchs, Switzerland; 1 ml/kg body wt daily for two days), the others received equal amounts of intraductal saline. Both solutions were infused continuously through the indwelling biliary drainage at a rate of 1 
where h is equal to the maximum longitudinal axis and R, r are the maximal and minimal radius.'2 At autopsy specimens of the CBD, the liver and the duodenum were fixed with 10% formalin and then stained with haematoxylin and eosin for light microscopy evaluation.
HUMAN EXPERIMENTS
A 68 year old male patient and a 75 year old female patient from a previously published series4 were contacted one year after intraductal MTBE administration for retained CBD stones. In the first patient MTBE (11 ml over six hours equivalent to 0-2 ml/kg body wt) was instilled into the CBD through a Teflon intracatheter (5.7F, Olstyke, Denmark) introduced into the T-tube (15 F). At 30 minute intervals, 1 ml MTBE was infused after aspiration of bile and residual MTBE. Gentle aspiration and reinfusion were continuously undertaken to generate stirring. The total amount of MTBE reaspirated during the entire procedure was 4 ml. In the second patient MTBE was infused on two consecutive days. Every 30 minutes, 0-7 ml MTBE was instilled into the CBD for a total of about 11 ml/day for two days (total of 22 ml equivalent to 0-32 ml/kg body wt). By reaspiration, 8 ml MTBE was retrieved. In both cases, no attempt was made to retain the MTBE infused into the CBD by a distal balloon. The two subjects volunteered to participate in this study by undergoing a complete reassessment of hepatic and pancreatic function tests and an intravenous cholangiography. The volume of the common bile duct was calculated by radiographs as previously described and was compared with the pretreatment values as well as with the values obtained in control subjects. Table 1 lists the demographic and clinical characteristics of all the patients. As MTBE treated subjects underwent a subsequent course of intraductal monooctanoin, both patients treated with intraductal saline or monooctanoin served as controls. The modalities of the saline washouts after intravenous ceruletide and of monooctanoin administration were similar to those previously described.'3"4 Briefly, after an overnight fast, the patients received iv ceruletide (Takus, Farmitalia, Milan, Italy) at the dose of 2 ng/kg body wt/min for one hour plus intraductal sterile saline (1000-2000 ml). During the infusion an online mono- 
Results
All the animals remained alive for the entire experimental period. During intraductal MTBE instillation, transient vomiting, dyspnoea and somnolence occurred, and the characteristic odour of the compound was detected on the breath of the animals. Rabbits given MTBE showed significant deviations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) from the controls ( Table 2 ). Bile cultures gave negative results in all the cases. The cholangiographies carried out in basal conditions and one week after the last intraductal infusion revealed a marked increase of the post-treatment CBD size in MTBE v control rabbits (Figs 1 and 2) . Accordingly, the posttreatment CBD volume was significantly greater in MTBE treated rabbits than in controls ( (Figs 3 and 4) . Table 4 reports the volume of the CBD before and after the intraductal treatment. Subjects treated with saline or monooctanoin had a marked decrease of the CBD volume in respect to baseline value. On the other hand, the two patients given MTBE exhibited no appreciable change in CBD volume one year later. 
Discussion
The experiments indicated that the direct infusion of moderate amounts of MTBE into the CBD produces biochemical and histological evidence of cholangitis in rabbits. These findings add to the previous data by Allen et all who described some adverse effects in dogs treated with MTBE instilled into the gall bladder. In particular, they referred to an increase in serum alkaline phosphatase, inflammatory changes in gall bladder specimens as well as mild duodenitis in some animals. They also reported strong analogies between MTBE and diethyl ether, which is known to exert irritating effects on skin and mucous membranes. In our experimental conditions the toxicity of MTBE appeared more striking as we also noted a significant increase in serum ALT and AST: the discrepancy may be related to the modalities of MTBE administration as well as to the different susceptibility of the animal species. In this regard, it 
